Respiratory syncytial virus (RSV) infection in the first year of life increases the risk of asthma in children. The study included 1,741 children, 54% of whom had RSV infection in infancy. Children infected with RSV had a 26% higher risk of asthma at age 5 years compared with children without RSV infection. It has been estimated that prevention of RSV in newborns could reduce the incidence of asthma in children by approximately 15%[1][3]. Immunoprophylaxis with palivizumab, which is administered mainly to at-risk groups such as preterm infants, significantly reduces the number of hospitalizations for RSV infection and thus the potential risk of developing asthma. Palivizumab can prevent approximately one-third of asthma cases associated with RSV infection[2][6]. RSV causes severe respiratory disease, particularly in very young children and preterm infants, and its prevention is key to reducing long-term respiratory sequelae, including asthma[4][5].